Jacobs Levy Equity Management, Inc Ultragenyx Pharmaceutical Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 97,960 shares of RARE stock, worth $4.38 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
97,960
Previous 634,327
84.56%
Holding current value
$4.38 Million
Previous $26.1 Million
79.13%
% of portfolio
0.02%
Previous 0.11%
Shares
17 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.7MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$445 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$251 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$229 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$186 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$137 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.13B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...